Repligen (NASDAQ:RGEN – Get Free Report) was downgraded by Benchmark from a “buy” rating to a “hold” rating in a report released on Monday, FinViz reports. Other equities research analysts also recently issued research reports about the company. UBS Group lowered their price target on Repligen from $210.00 to $170.00 and set a “buy” rating […]
Shares of Repligen Co. (NASDAQ:RGEN – Get Free Report) have earned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year price objective among […]
Banque Cantonale Vaudoise Makes New Investment in Repligen Co (NASDAQ:RGEN) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
William Blair Weighs in on Repligen Co s Q4 2023 Earnings (NASDAQ:RGEN) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Repligen (NASDAQ:RGEN – Free Report) had its price objective trimmed by Royal Bank of Canada from $207.00 to $200.00 in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. Other equities analysts have also issued research reports about the stock. Craig Hallum dropped […]